Market Data
Market Cap₹3,714.94 Cr.
52W High₹3,866.55
Current Price₹3,580.25
52W Low₹828.8
Down from 52W High7.4 %
Face Value₹10
Performance
ROCE25.39 %
ROE24.44 %
EPS (TTM)₹24.69
EPS Prev Qtr₹24.39
EPS Last Year₹13.6
EBITDA Qtr₹36.02 Cr.
Book Value₹320
Financial Health
Debt/Equity0.39
Debt/Profit1.61
Total Assets₹592.209 Cr.
Promoter Holding54.86 %
Earning Power19.43 %
Valuation
Stock P/E45.84
Industry P/E33.81
Price to Book11.2
Price to Sales6.71
Graham Number₹749.49
Key Metrics
Face Value
₹10
About Kwality Pharmaceuticals Ltd
Healthcare · Pharmaceuticals
Kwality Pharmaceuticals Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹3,714.94 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a healthy ROCE of 25.39%, indicating efficient use of capital.
- ROE stands at 24.44%, reflecting strong returns generated on shareholders' equity.
- The promoter holding is 54.86%, suggesting significant management control and alignment of interests.
Weaknesses
- The P/E ratio of 44.11 is relatively high, indicating that the stock may be overvalued.
- The P/B ratio of 10.78 suggests that the market values the company at a premium over its book value.
- The company has a Debt to Equity ratio of 0.39, indicating a moderate level of financial leverage.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 111.05 | 123.44 | 157.11 | 162.35 |
| ↳ QoQ Growth | - | +11.2% | +27.3% | +3.3% |
| Expenses | 90.66 | 98.31 | 123.62 | 126.33 |
| Operating Profit | 20.4 | 25.13 | 33.5 | 36.02 |
| OPM % | 18.37% | 20.36% | 21.32% | 22.19% |
| Other Income | 0.9 | 0.53 | 1.06 | 0.62 |
| Interest | 2.84 | 2.48 | 2.89 | 2.66 |
| Depreciation | 4.96 | 4.82 | 5.26 | 4.99 |
| EBITDA | 25.36 | 29.95 | 38.76 | 41.01 |
| EBITDA Margin % | 22.84% | 24.26% | 24.67% | 25.26% |
| Profit Before Tax | 18.45 | 22.35 | 31.67 | 33.99 |
| Tax % | 23.47% | 28.41% | 20.08% | 24.6% |
| Net Profit | 14.12 | 16 | 25.31 | 25.62 |
| ↳ QoQ Growth | - | +13.3% | +58.2% | +1.2% |
| EPS | 13.6 | 15.42 | 24.39 | 24.69 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 10.38 | 10.3762 |
| Reserves | 253.67 | 321.2194 |
| Borrowings | 112.45 | 130.46 |
| Other Liabilities | 70.77 | 130.15 |
| Total Liabilities | 447.27 | 592.2091 |
| Fixed Assets | 143.98 | 155.5713 |
| CWIP | 0 | 17.0062 |
| Investments | 0 | 0 |
| Other Assets | 303.29 | 419.63 |
| Total Assets | 447.27 | 592.2091 |
Cash Flows
| Mar 2026 | |
|---|---|
| Cash from Operating Activity | 17.057 |
| Cash from Investing Activity | -34.9096 |
| Cash from Financing Activity | 7.0396 |
| Net Cash Flow | -10.813 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 54.83% | 54.83% | 54.87% | 54.86% |
| FIIs % | 0% | 0.5% | 2.79% | 3.13% |
| DIIs % | 0.33% | 0.33% | 0.36% | 0.56% |
| Public % | 33.68% | 33.03% | 31.64% | 31.03% |
| No. of Shareholders | 11,595 | 10,709 | 10,555 | 13,279 |
Major Shareholders (>1%)
- Ramesh AroraPromoter and Promoter Group26.03%
- Ajay AroraPromoter and Promoter Group13.60%
- Aditya AroraPromoter and Promoter Group11.96%
- Deepak BansalPublic Shareholding8.39%
As of 2026-06-30View all shareholders →